Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Pfizer | INDUSTRY |
Not provided
Not provided
Not provided
Not provided
This study is observational, multicenter and prospective study for surveillance of the use of new antibiotics in pediatrics for treated pediatrics infections due to multi-resistant bacteria
The main of this study is to evaluate the relevance of prescribing "new antibiotics" according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation
As this is a surveillance study, the clinical and biological characteristics of the children included will be described.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Relevance of prescribing "new antibiotics" according to patient status | Type of new antibiotics prescribed for pediatrics infections caused by multi-resistant bacteria according to the antibiogram of the isolated bacteria or in the absence of bacteriological documentation | 1 year |
| Relevance of prescribing "new antibiotics" | how are used new antibiotics prescribed for pediatrics infections caused by multi-resistant bacteria | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Describe Bacterial epidemiology of infections associated with prescription of new antibiotics | Characteristic of bacteria associated with prescription of new antibiotics | 1 year |
| Identify Risks factors for multi-resistant bacteria |
Not provided
Inclusion Criteria:
Children under 18 years of age
Hospitalized in France in a hospital center working with the ACTIV/GPIP network
Treated with one or more of the following antibiotics:
In association with a documented infection performed by:
Blood culture
Normally sterile site
Urine sampling if the bacteria was considered responsible for the infection (associated with a leukocyturia ≥10,0000)
Respiratory specimens if the bacteria was considered responsible for the infection
Sampling on material such as:Intubation probe, Orthopedic, Urological, Central Nervous System (CNS),....
Exclusion Criteria:
Not provided
Not provided
Not provided
pediatrics patients infected by multi-resistant bacterial, treated by new antibiotics
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Levy Corinne | Association Clinique Thérapeutique Infantile du val de Marne | Study Director |
| Cohen Robert | Association Clinique Thérapeutique Infantile du val de Marne | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| ACTIV | Créteil | 94000 | France |
Not provided
Not provided
Not provided
Not provided
Type of conditions responsible of multi-resistant such as comorbidities, travel, previous hospitalization, previous antibiotherapy,
| 1 year |
| Describe Context of drug Prescription | How antibiotics medical prescriptions are controlled and validated | 1 year |
| Department involved in medical prescribing | Number of department involved in medical prescriptions | 1 year |
| Describe Associated Antibiotherapies type | Type of drug association prescribed | 1 year |
| Describe Associated Antibiotherapies | Number of drug association prescribed | 1 year |
| Describe patients outcome | Proportion of patients clinically and bacteriologically recovered | 1 year |